Can Psoriasis Therapy Lower CV Event Risk in Psoriasis Patients?

heart

Patients with psoriasis treated with tumor necrosis factor-alpha inhibitors (TNFis) had a significantly lower risk for cardiovascular events compared with patients treated with phototherapy, according to the findings of a recent study.

In their observational study, the researchers identified patients with psoriasis using a large US administrative claims database. Patients were separated into 2 cohorts based on whether they were treated with TNFis (n=11,410) or phototherapy (n=12,433). The researchers used multivariate Cox proportional hazards models to compare the cardiovascular event risk between the 2 cohorts.
_________________________________________________________________________
RELATED CONTENT
Psoriasis Patients Underdiagnosed For CV Risk Factors
Psoriasis Therapy Significantly Reduces Aortic Inflammation
_________________________________________________________________________
Compared with patients treated with phototherapy, those treated with TNFis had a lower risk for cardiovascular events (adjusted hazard ratio: 0.77). The risk reduction associated with 6 months of cumulative exposure was 11.2% larger for patients treated with TNFis compared to phototherapy (p<0.05).

“Psoriasis patients treated with TNFis exhibited a lower cardiovascular event risk than patients treated with phototherapy,” the researchers concluded. “Cumulative exposure to TNFis was associated with an incremental cardiovascular risk reduction compared to phototherapy.”

—Melissa Weiss

Reference:

Wu JJ, Sundaram M, Cloutier M, et al. The risk of cardiovascular events in psoriasis patients treated with tumor necrosis factor-alpha inhibitors versus phototherapy: an observational cohort study [published online February 27, 2018]. J Am Acad Dermatolhttps://doi.org/10.1016/j.jaad.2018.02.050.